The Latest Breaking News from FDA

If insurers or governments don't step up, addiction experts fear it could widen health disparities and undercut the FDA's goals of addressing a "dire public health need."

On Wednesday, the FDA approved Narcan for over-the-counter use in the form of a nasal spray, previously available only by prescription.

‘My rear end would get super inflamed and it would get really really hard and really hot,’ she said about side effects of injections

On March 29, 2023, the U.S. Food and Drug Administration approved Narcan for over-the-counter sale. Narcan is the 4-milligram nasal spray version of naloxone, a medication that can quickly counteract an opioid overdose.

And this lawsuit faces many of the same administrative law hurdles as does AHM v. FDA.

The spray version of naloxone will be available for sale by late summer. Experts praised the move to make it more accessible amid the national opioid crisis but are concerned it may be too expensive for some people.

The life-saving drug stops opioid overdoses as they happen, restoring breathing and preventing death. Why did it take so long for the FDA to expand its use?

The U.S. Food and Drug Administration announced Wednesday that it had approved Narcan for over-the-counter, nonprescription use.

The decision comes as a bid to widen access to the life-saving drug as the US struggles with a wave of overdose deaths.

The Food and Drug Administration appears poised to make available the COVID-19 vaccines that target omicron as a second booster for people with weak immune systems and those ages 65 and older.

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…